eligibility_summary
Adults ≥18 with relapsed/refractory MM after PI, IMiD, and anti‑CD38, 1–4 prior lines, BCMA ADC/CAR‑T allowed (6‑mo washout). Require measurable disease, ECOG 0–2, adequate blood/liver/renal/Ca, NYHA ≤2, contraception/neg test, controlled HIV/HBV/HCV allowed. Exclusions: other plasma-cell disorders, CNS/cord disease, active autoimmune therapy, recent live vaccine, active infection, chronic GVHD on >20 mg steroids, hypersensitivity, major comorbidity or psych/substance use, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: MMRC Horizon One adaptive platform in relapsed/refractory multiple myeloma. Interventions: Teclistamab (Tecvayli). Reference arm: standard-of-care teclistamab monotherapy, experimental arm: investigational dosing/schedules of teclistamab. Drug type/mechanism: humanized IgG4 bispecific T‑cell–redirecting antibody (CD3×BCMA). It binds BCMA (TNFRSF17) on malignant plasma cells and CD3 on T cells, forming an immunologic synapse that activates TCR/CD3 signaling, induces cytokine release and perforin/granzyme-mediated cytotoxicity, leading to death of BCMA+ myeloma cells and plasma cell depletion. Targets: BCMA-expressing myeloma/plasma cells, CD3+ T lymphocytes. Pathways engaged: BCMA survival axis (APRIL/BAFF), T-cell activation (TCR/CD3→NFAT/NF-κB), and cytotoxic effector pathways. Type: antibody-based immunotherapy (bispecific T-cell engager).